Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Shanghai Haohai Biological Technology Co Ltd
Cash & Cash Equivalents
Shanghai Haohai Biological Technology Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
|
Cash & Cash Equivalents
¥2.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
¥15B
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash & Cash Equivalents
¥7.5B
|
CAGR 3-Years
77%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash & Cash Equivalents
¥6.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash & Cash Equivalents
¥3.8B
|
CAGR 3-Years
75%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Cash & Cash Equivalents
¥1.5B
|
CAGR 3-Years
135%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Haohai Biological Technology Co Ltd
Glance View
Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.
See Also
What is Shanghai Haohai Biological Technology Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.7B
CNY
Based on the financial report for Dec 31, 2023, Shanghai Haohai Biological Technology Co Ltd's Cash & Cash Equivalents amounts to 2.7B CNY.
What is Shanghai Haohai Biological Technology Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
14%
Over the last year, the Cash & Cash Equivalents growth was 8%. The average annual Cash & Cash Equivalents growth rates for Shanghai Haohai Biological Technology Co Ltd have been -4% over the past three years , 14% over the past five years .
You don't have any saved screeners yet